Antiviral Response across Genotypes after Treatment of Chronic Hepatitis B Patients with the Therapeutic Vaccine NASVAC or Pegylated Interferon

An open-level, randomized and treatment-controlled clinical trial has shown that a therapeutic vaccine containing hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg) (NASVAC) is endowed with antiviral and liver protecting capacity and is safer than pegylated interferon (Peg-IFN)...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Mahtab, Mamun, Akbar, Sheikh Mohammad Fazle, Yoshida, Osamu, Aguilar, Julio Cesar, Guillen, Gerardo, Hiasa, Yoichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221800/
https://www.ncbi.nlm.nih.gov/pubmed/37243066
http://dx.doi.org/10.3390/vaccines11050962

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221800/
https://www.ncbi.nlm.nih.gov/pubmed/37243066
http://dx.doi.org/10.3390/vaccines11050962

Ejemplares similares